Related Experiment Video
Updated: Apr 4, 2026
Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic
Andreas Baumbach1, Cody Pietras2, Alexandra Lansky2
1a 1 Bristol Heart Institute, University Hospitals Bristol, Bristol , Royal Infirmary, Upper Maudlin St, Bristol, Avon BS2 8HW, UK.
Insights
Transcatheter aortic valve implantation can cause brain embolic events. Using the TriGuard embolic deflection device may reduce these events and improve neurocognitive function after the procedure.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Biomedical Engineering
Background:
- Transcatheter aortic valve implantation (TAVI) is associated with a significant risk of embolic ischemic cerebral events.
- These events can range from silent brain lesions to severe strokes, leading to neurocognitive impairment such as memory loss.
Abstract:
The incidence of embolic ischemic cerebral events during transcatheter aortic valve implantation remains high. The effects range from clinically silent embolic lesions in the brain to severe disabling stroke. Memory loss and other functional neurocognitive impairment are a direct result of embolic strokes. The TriGuard embolic deflection device is a nitinol frame filter that is placed across all three aortic cerebral vessel ostia to prevent particles from entering the brain circulation during the procedure. The results of clinical studies suggest that this procedure can lead to a reduction of embolic events, and an improvement of neurocognitive function when compared with unprotected transcatheter aortic valve implantation.
